140 related articles for article (PubMed ID: 16125497)
1. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II).
Brodine WN; Tung RT; Lee JK; Hockstad ES; Moss AJ; Zareba W; Hall WJ; Andrews M; McNitt S; Daubert JP;
Am J Cardiol; 2005 Sep; 96(5):691-5. PubMed ID: 16125497
[TBL] [Abstract][Full Text] [Related]
2. Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
Ruwald MH; Abu-Zeitone A; Jons C; Ruwald AC; McNitt S; Kutyifa V; Zareba W; Moss AJ
J Am Coll Cardiol; 2013 Oct; 62(15):1343-50. PubMed ID: 23770172
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
[TBL] [Abstract][Full Text] [Related]
4. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
Ruwald MH; Ruwald AC; Jons C; Alexis J; McNitt S; Zareba W; Moss AJ
J Am Coll Cardiol; 2013 Apr; 61(14):1518-26. PubMed ID: 23500269
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
[TBL] [Abstract][Full Text] [Related]
6. Comparison of age (<75 Years versus ≥75 Years) to risk of ventricular tachyarrhythmias and implantable cardioverter defibrillator shocks (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
Aktas MK; Goldenberg I; Moss AJ; Huang DT; Kutyifa V; Wang PJ; Brenyo A; McNitt S; Zareba W; Barsheshet A
Am J Cardiol; 2014 Dec; 114(12):1855-60. PubMed ID: 25438913
[TBL] [Abstract][Full Text] [Related]
7. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
Vyas AK; Guo H; Moss AJ; Olshansky B; McNitt SA; Hall WJ; Zareba W; Steinberg JS; Fischer A; Ruskin J; Andrews ML;
J Am Coll Cardiol; 2006 Feb; 47(4):769-73. PubMed ID: 16487843
[TBL] [Abstract][Full Text] [Related]
8. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
Haigney MC; Zareba W; Gentlesk PJ; Goldstein RE; Illovsky M; McNitt S; Andrews ML; Moss AJ;
J Am Coll Cardiol; 2004 Oct; 44(7):1481-7. PubMed ID: 15464332
[TBL] [Abstract][Full Text] [Related]
9. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
[TBL] [Abstract][Full Text] [Related]
10. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
Go AS; Yang J; Gurwitz JH; Hsu J; Lane K; Platt R
Am J Cardiol; 2007 Aug; 100(4):690-6. PubMed ID: 17697830
[TBL] [Abstract][Full Text] [Related]
12. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
[TBL] [Abstract][Full Text] [Related]
13. The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: implications for timing of implantable cardioverter-defibrillator implantation.
Teeter WA; Thibodeau JT; Rao K; Brickner ME; Toto KH; Nelson LL; Mishkin JD; Ayers CR; Miller JG; Mammen PP; Patel PC; Markham DW; Drazner MH
Am Heart J; 2012 Sep; 164(3):358-64. PubMed ID: 22980302
[TBL] [Abstract][Full Text] [Related]
14. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Philbert BT; Torp-Pedersen C; Riahi S; Jøns C
Europace; 2018 Sep; 20(FI2):f217-f224. PubMed ID: 29684191
[TBL] [Abstract][Full Text] [Related]
15. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II.
Goldenberg I; Moss AJ; Hall WJ; McNitt S; Zareba W; Andrews ML; Cannom DS;
Circulation; 2006 Jun; 113(24):2810-7. PubMed ID: 16769917
[TBL] [Abstract][Full Text] [Related]
16. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
[TBL] [Abstract][Full Text] [Related]
17. Relation of ventricular tachycardia/fibrillation to beta-blocker dose maximization guided by pacing mode analysis in nonpacemaker-dependent patients with implantable cardioverter-defibrillator.
Deftereos S; Giannopoulos G; Kossyvakis C; Kaoukis A; Raisakis K; Panagopoulou V; Ntzouvara O; Perpinia A; Rentoukas I; Pyrgakis V; Manolis AS; Stefanadis C
Am J Cardiol; 2011 Jun; 107(12):1812-7. PubMed ID: 21481829
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
[TBL] [Abstract][Full Text] [Related]
19. Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dose-dependent effect.
Jiménez-Candil J; Hernández J; Martín A; Ruiz-Olgado M; Herrero J; Ledesma C; Moríñigo J; Martín-Luengo C
Europace; 2010 Sep; 12(9):1231-8. PubMed ID: 20525727
[TBL] [Abstract][Full Text] [Related]
20. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II.
Goldenberg I; Gillespie J; Moss AJ; Hall WJ; Klein H; McNitt S; Brown MW; Cygankiewicz I; Zareba W;
Circulation; 2010 Sep; 122(13):1265-71. PubMed ID: 20837894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
